ArticleClinical kidney journal2024

Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial.

Phil McEwan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.